Dr. John C. Reed, M.D., Ph.D. has been the Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 2, 2013. Dr. Reed serves as an Assistant Professor, Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. He is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida and in San Diego State University's Biology department. Dr. Reed co-founded IDUN Pharmaceuticals Inc., in 1993. He served as an Advisor and Consultant to Berlex Laboratories Inc., DAKO Inc., Genta Inc., PharMingen Inc., Rigel Pharmaceuticals Inc., Stratagene Inc., Abbott, Isis and other biotechnology and pharmaceutical companies, as well as Robertson Stephens investment bankers. Dr. Reed served as the President and Chief Executive Officer of Sanford-Burnham Medical Research Institute since January 2002. He joined Burnham Institute as Deputy Director of the Cancer Center beginning in 1994, as Scientific Director since 1995 and as Cancer Center Director since 2002 and also served as Director of Oncogene and Tumor Suppressor Gene Program. He has also served in various capacities as an Advisor to the National Cancer Institute, the American Association for Cancer Research (AACR) and American Cancer Society. From 1989 to 1992, he worked as Assistant Director, Laboratory of Molecular Diagnosis at the hospital of the University of Pennsylvania. He served as a Director of Stratagene Corporation since June 2004. He has been Director of Pharmion Corp., since June 2, 2005. He served as a Member of Scientific Advisory Board at Predictive Biosciences, Inc. since May 2007. He served as Member of Advisory Board at Sanford-Burnham Medical Research Institute. He serves on the board of Directors of Stratagene Inc. and BIOCOM. He also serves as a Member of the Board of Trustees and Member of Scientific Advisory Boardat The Burnham Institute. He served as Member of Scientific Advisory Board at Guava Technologies Inc. Dr. Reed served as a Director of ISIS Pharmaceuticals Inc., from February 2002 February 12, 2013. He served as a Director of Repros Therapeutics Inc. from September 29, 2008 to November 1, 2009. He served as a Director of Clovis Oncology, Inc. until February 14, 2013. He served as a Director of IDUN Pharmaceuticals, Inc., and Sanford-Burnham Medical Research Institute. He served as a Member of the Scientific Advisory Board at IDUN Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board at Cengent Therapeutics Inc. Dr. Reed is an associate member of UCSD's Cancer Center. He serves on the Editorial boards of over 12 scientific journals. Dr. Reed is the 2003 recipient of the Bristol-Myers-Squibb unrestricted grant for distinguished cancer research. According to the Institute for Scientific Information, Dr. Reed has published more papers related to apoptosis and has received more citations for his publications than any other scientist in the world. He is the Author of approximately 600 peer-reviewed scientific articles and nearly 75 book chapters. He was also a postdoctoral fellow in molecular biology at the Wistar Institute of Anatomy and Biology. Dr. Reed holds a B.A. in Biochemistry from the University of Virginia and an M.D. in Medicine and a Ph.D. in Immunology from the University of Pennsylvania in 1986, where he also received his clinical and postdoctoral training.

 Clinical Pathology and Laboratory Medicine